How Neuropeptides Drive Mucus Problems in Asthma, COPD, and Cystic Fibrosis | Research

The takeaway

Neuropeptides released by airway nerves play a major but underappreciated role in driving mucus overproduction and other symptoms across asthma, COPD, and cystic fibrosis.

3 major diseases, 1 shared problem
Neuropeptide-driven mucus hypersecretion is a common feature across asthma, COPD, and cystic fibrosis — yet remains an underexplored therapeutic target

What the researchers found

This review consolidates evidence on how neuropeptides — signaling molecules released by nerves in the airways — contribute to asthma, COPD, and cystic fibrosis. The nervous system doesn't just control breathing; it actively drives disease processes like excessive mucus production, airway smooth muscle contraction, and inflammation through peptides like substance P, CGRP, VIP, and others.

The authors highlight that mucus hypersecretion is a shared feature across all three diseases, and neuropeptides play a central but underappreciated role in driving it. They also identify several less-studied neuropeptides that deserve more research attention as potential therapeutic targets.

Why it matters

Asthma, COPD, and cystic fibrosis collectively affect hundreds of millions of people worldwide. Current treatments often focus on inflammation or infection, but this review argues that the nervous system's peptide signaling is an overlooked driver of disease symptoms — particularly the dangerous mucus buildup that blocks airways. Understanding which neuropeptides are involved could open new treatment approaches targeting the neural side of these diseases.

The numbers in context

3 diseases reviewed (asthma, COPD, cystic fibrosis) · Focus on mucus hypersecretion as common feature · Multiple neuropeptides examined including substance P, CGRP, VIP

How the study worked

This is a narrative review that synthesizes published research on neuropeptides in airway diseases. The authors examined existing literature on both well-studied and lesser-known neuropeptides, with particular emphasis on their roles in mucus secretion and airway pathology across asthma, COPD, and cystic fibrosis.

Who was studied

Review covering human and animal studies on airway diseases

What this study cannot tell us

As a review article, this paper synthesizes existing findings rather than presenting new experimental data. The depth of evidence varies considerably between the neuropeptides discussed — some have extensive research support while others are largely speculative. The review acknowledges significant knowledge gaps, particularly regarding the precise mechanisms by which neuropeptides drive mucus phenotypes in each disease.

How to read the evidence

This is a narrative review synthesizing evidence from multiple studies. While it provides a valuable overview and identifies important knowledge gaps, it does not present new experimental data or use systematic review methodology, placing it at a moderate evidence level.

When this study was published

Published in 2018, this review provides a relatively recent synthesis of the field. The fundamental neuropeptide biology described remains current, though specific therapeutic developments may have advanced since publication.

The bigger picture

Peptide signaling extends far beyond hormones and metabolism — neuropeptides are active players in disease processes throughout the body. This review highlights how the nervous system's peptide messengers contribute to some of the most common respiratory diseases, suggesting that peptide-targeted therapies could complement existing anti-inflammatory and antimicrobial treatments for airway diseases.

Questions still open

Could drugs targeting specific airway neuropeptides reduce dangerous mucus buildup in cystic fibrosis patients?
Why have the lesser-studied neuropeptides identified in this review received so little research attention despite their potential relevance?
Would combining neuropeptide-targeted therapies with existing treatments improve outcomes in severe COPD or asthma?

Common questions

What are neuropeptides and how do they affect your lungs?

Neuropeptides are small signaling molecules released by nerve endings throughout your body, including in your airways. In the lungs, they help control protective functions like cough and mucus production. But in diseases like asthma, COPD, and cystic fibrosis, neuropeptide signaling can go haywire — causing too much mucus, excessive airway narrowing, and worsening inflammation.

Could targeting neuropeptides lead to new treatments for lung diseases?

That's the hope. Current treatments mostly focus on reducing inflammation or fighting infection, but they don't address the neural signaling that drives mucus overproduction. By targeting specific neuropeptides or their receptors in the airways, researchers may be able to develop therapies that tackle symptoms from a completely different angle.

Read the original research

Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis.

Respiratory research, 19(1), 149

View on PubMed ↗Publisher’s paper ↗

Citation

Atanasova, Kalina R; Reznikov, Leah R. (2018). Neuropeptides in asthma, chronic obstructive pulmonary disease and cystic fibrosis.. Respiratory research, 19(1), 149. https://doi.org/10.1186/s12931-018-0846-4